<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00950664</url>
  </required_header>
  <id_info>
    <org_study_id>H-0902-049-272</org_study_id>
    <nct_id>NCT00950664</nct_id>
  </id_info>
  <brief_title>A Study to Compare Dysport® and Botox® in the Treatment of Cervical Dystonia</brief_title>
  <official_title>A Double Blind, Randomized, Multi-center, Cross-over Study to Demonstrate the Non-inferiority of Dysport® in Comparison With Botox®, Assuming a Bioequivalence Ratio of 2.5:1 Units, in the Cervical Dystonia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ipsen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical Research Collaborating Center, Seoul, Korea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. to examine the non-inferiority of Dysport in the clinical efficacy and safety in
           comparison with Botox®, assuming a bioequivalence ratio of 2.5:1 units, in the treatment
           of Cervical dystonia.

        2. double blind, randomised, multi center, crossover study
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Prospective, randomized, head-to-head, double-blind, cross-over study.

        2. Total patients: A group 51, B group 51

        3. Study duration: 16 + 4 + 16 weeks. Eligible patients will be randomised at baseline to
           receive either Dysport® or Botox® and monitored at weeks 2, 4, 8, 12, 16 weeks. After 4
           weeks of wash out period, then the patients get the other treatment (i.e, Patients who
           have got Dysport will be then administered with Botox)

        4. Compare the TSUI change score from baseline to 4 weeks after injection.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction of Total Tsui Score at 4 Weeks From Baseline</measure>
    <time_frame>4 weeks after injection from baseline</time_frame>
    <description>Tsui scale is an impairment scale which evaluates the amplitude and duration of sustained posture and intermittent movements of the head, as well as the presence of shoulder elevation and tremor.
Tsui scale (range: 0-25, higher values represent worse cervical dystonia.) Negative numbers to represent decreases of Tsui scale.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction of Total TWSTRS Score at 4 Weeks From Baseline</measure>
    <time_frame>4 weeks after injection from baseline</time_frame>
    <description>TWSTRS (Toronto western spasmodic torticollis rating scale) The TWSTRS is a composite scale which covers different features of cervical dystonia(CD).
The first part is based on the physical findings (severity subscale), the second part rates disability, and the third part pain.
(range: 0-80, higher values represent worse cervical dystonia.) Details of the TWSTRS are displayed on the Web site http://www.wemove.org. Negative numbers to represent decreases of TWSTRS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CGI-I (Clinical Global Impression of Illness)</measure>
    <time_frame>4, 8, 12 and 16 weeks after injection</time_frame>
    <description>The proportion of patients with 'normal/ not at all ill' or 'borderline mildly ill' on the CGI (Clinical global impression of illness, CGI-I)
1 = normal / not at all ill'; 2 = 'borderline mildly ill'; 3 = 'mildly ill'; 4 = 'moderlately ill'; 5 = 'markedly ill'; 6 = 'severely ill'; 7 = 'the most extremely ill'.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PGI-I (Patient's Global Impression of Improvement)</measure>
    <time_frame>4, 8, 12 and 16 weeks after injection</time_frame>
    <description>The proportion of patients with 'very much improved' or 'much improved' on the PGI (Patient's global impression of impairment, PGI-I)
1 = very much improved, 2= much improved, 3 = slightly improved, 4 = no change, 5 = slightly aggravated, 6 = much aggravated, and 7 = very much aggravated</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Reduction of Tsui Score at Each Visit From Baseline</measure>
    <time_frame>8, 12 and 16 weeks after injection</time_frame>
    <description>Tsui scale (range: 0-25, higher values represent worse cervical dystonia.) Negative numbers to represent decreases of Tsui scale.</description>
  </other_outcome>
  <other_outcome>
    <measure>Reduction of Total TWSTRS at Each Visit From Baseline</measure>
    <time_frame>8, 12 and 16 weeks after injection</time_frame>
    <description>TWSTRS scale (Toronto western spasmodic torticollis rating scale, range: 0-80, higher values represent worse cervical dystonia.) Negative numbers to represent decreases of TWSTRS scale.</description>
  </other_outcome>
  <other_outcome>
    <measure>Reduction of Pain Associated With Cervical Dystonia at Each Visit From Baseline</measure>
    <time_frame>4, 8, 12 and 16 weeks after injection</time_frame>
    <description>Pain subscale of TWSTRS scale.(Range: 0-20) Negative numbers to represent decreases of TWSTRS pain subscale.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">103</enrollment>
  <condition>Cervical Dystonia</condition>
  <arm_group>
    <arm_group_label>Dysport® to Botox®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dysport® injection in first intervention period and Botox® in second intervention period (after washout period) cross over injection of Dysport® (abobotulinumtoxinA) and Botox® (onabotulinumtoxinA)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Botox® to Dysport®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Botox® injection in first intervention period and Dysport® in second intervention period (after washout period) cross over injection of Dysport® (abobotulinumtoxinA) and Botox® (onabotulinumtoxinA)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dysport® (abobotulinumtoxinA)</intervention_name>
    <description>Cross over injection of Dysport® (&lt;500IU), Botox® (200IU)assuming a bioequivalence ratio of 2.5:1 units</description>
    <arm_group_label>Dysport® to Botox®</arm_group_label>
    <arm_group_label>Botox® to Dysport®</arm_group_label>
    <other_name>Dysport® (abobotulinumtoxinA)injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Botox® (onabotulinumtoxinA)</intervention_name>
    <description>Cross over injection of Dysport® (&lt;500IU), Botox® (200IU)assuming a bioequivalence ratio of 2.5:1 units</description>
    <arm_group_label>Dysport® to Botox®</arm_group_label>
    <arm_group_label>Botox® to Dysport®</arm_group_label>
    <other_name>Botox® (onabotulinumtoxinA)injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients ≥ 18 years of age of both genders,

          -  Cervical dystonia

          -  symptoms with a minimum duration of 18 months,

          -  Negative pregnancy test in sexually active women,

          -  Able to participate in the study (understand goals of botulinum toxin A treatment and
             sign Informed Consent Form).

        Exclusion Criteria:

          -  Patient with cervical contractures

          -  Known significant underlying dysphasia

          -  Patients who have received botulinum toxin treatment within the past 4 months.

          -  Contraindication to botulinum toxin treatment

          -  Any disease that might affect neuromuscular function (Myasthenia Gravis, Eaton-Lambert
             syndrome, ALS …)

          -  Patients who have received oral anti-spasticity medication, phenol therapy, myotomy or
             denervation surgery, deep brain stimulation for cervical dystonia,

          -  Patients who required more than 500 units of Dysport or 200 units of Botox.

          -  Any concomitant treatment that could interfere with the action of botulinum toxin,

          -  Subjects having participated within the last 3 months or currently participating in an
             investigational drug study,

          -  Pregnancy,

          -  Lactation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Beom S Jeon, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bundang Seoul Natiuonal University Hospital</name>
      <address>
        <city>Seongnam</city>
        <state>Gyeong-gi</state>
        <zip>463-070</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dong-A University Hospital</name>
      <address>
        <city>Busan</city>
        <zip>602-715</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hanyang University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>133-792</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boramae City Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>156-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 29, 2009</study_first_submitted>
  <study_first_submitted_qc>July 30, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 3, 2009</study_first_posted>
  <results_first_submitted>February 8, 2013</results_first_submitted>
  <results_first_submitted_qc>August 5, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 11, 2013</results_first_posted>
  <last_update_submitted>June 13, 2017</last_update_submitted>
  <last_update_submitted_qc>June 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>BS Jeon</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>cervical dystonia</keyword>
  <keyword>botulinum toxin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dystonia</mesh_term>
    <mesh_term>Dystonic Disorders</mesh_term>
    <mesh_term>Torticollis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>onabotulinumtoxinA</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants recruited from movement disorder clinics at 7 hospitals in Korea, between August 2009 and March 2010.</recruitment_details>
      <pre_assignment_details>103 participants recruited; 103 screened, 1 excluded (1 refused participation).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Dysport® First, Then Botox®</title>
          <description>Dysport® injection in first intervention period and Botox® in second intervention period (after washout period)</description>
        </group>
        <group group_id="P2">
          <title>Botox® First, Then Dysport®</title>
          <description>Botox® injection in first intervention period and Dysport® in second intervention period (after washout period)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="53"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Washout Period of 4 Weeks</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="48"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All analyses were performed on the modified intention-to-treat (mITT) basis, with all subjects included in the two treatment challenges.</population>
      <group_list>
        <group group_id="B1">
          <title>Dysport® First, Then Botox®</title>
          <description>Dysport® injection in first intervention period and Botox® in second intervention period (after washout period)</description>
        </group>
        <group group_id="B2">
          <title>Botox® First, Then Dysport®</title>
          <description>Botox® injection in first intervention period and Dysport® in second intervention period (after washout period)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="46"/>
            <count group_id="B2" value="48"/>
            <count group_id="B3" value="94"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="80"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.24" spread="11.44"/>
                    <measurement group_id="B2" value="53.35" spread="10.18"/>
                    <measurement group_id="B3" value="53.29" spread="10.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="57"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Korea, Republic of</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Reduction of Total Tsui Score at 4 Weeks From Baseline</title>
        <description>Tsui scale is an impairment scale which evaluates the amplitude and duration of sustained posture and intermittent movements of the head, as well as the presence of shoulder elevation and tremor.
Tsui scale (range: 0-25, higher values represent worse cervical dystonia.) Negative numbers to represent decreases of Tsui scale.</description>
        <time_frame>4 weeks after injection from baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dysport® (abobotulinumtoxinA)</title>
            <description>Dysport® administered in either first intervention period or second intervention period</description>
          </group>
          <group group_id="O2">
            <title>Botox® (onabotulinumtoxinA)</title>
            <description>Botox® administered in either first intervention period or second intervention period</description>
          </group>
        </group_list>
        <measure>
          <title>Reduction of Total Tsui Score at 4 Weeks From Baseline</title>
          <description>Tsui scale is an impairment scale which evaluates the amplitude and duration of sustained posture and intermittent movements of the head, as well as the presence of shoulder elevation and tremor.
Tsui scale (range: 0-25, higher values represent worse cervical dystonia.) Negative numbers to represent decreases of Tsui scale.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.98" spread="3.89"/>
                    <measurement group_id="O2" value="-4.77" spread="4.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>81 participants required to detect 5 difference in Tsui score, with 80% power. 20% drop out rate assumed, 102 participants needed. Alpha level of 0.05.</non_inferiority_desc>
            <p_value>0.05</p_value>
            <method>Paired-t test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Reduction of Total TWSTRS Score at 4 Weeks From Baseline</title>
        <description>TWSTRS (Toronto western spasmodic torticollis rating scale) The TWSTRS is a composite scale which covers different features of cervical dystonia(CD).
The first part is based on the physical findings (severity subscale), the second part rates disability, and the third part pain.
(range: 0-80, higher values represent worse cervical dystonia.) Details of the TWSTRS are displayed on the Web site http://www.wemove.org. Negative numbers to represent decreases of TWSTRS.</description>
        <time_frame>4 weeks after injection from baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dysport® (abobotulinumtoxinA)</title>
            <description>Dysport® administered in either first intervention period or second intervention period</description>
          </group>
          <group group_id="O2">
            <title>Botox® (onabotulinumtoxinA)</title>
            <description>Botox® administered in either first intervention period or second intervention period</description>
          </group>
        </group_list>
        <measure>
          <title>Reduction of Total TWSTRS Score at 4 Weeks From Baseline</title>
          <description>TWSTRS (Toronto western spasmodic torticollis rating scale) The TWSTRS is a composite scale which covers different features of cervical dystonia(CD).
The first part is based on the physical findings (severity subscale), the second part rates disability, and the third part pain.
(range: 0-80, higher values represent worse cervical dystonia.) Details of the TWSTRS are displayed on the Web site http://www.wemove.org. Negative numbers to represent decreases of TWSTRS.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.76" spread="10.25"/>
                    <measurement group_id="O2" value="-8.78" spread="10.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Reduction of Tsui Score at Each Visit From Baseline</title>
        <description>Tsui scale (range: 0-25, higher values represent worse cervical dystonia.) Negative numbers to represent decreases of Tsui scale.</description>
        <time_frame>8, 12 and 16 weeks after injection</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dysport® (abobotulinumtoxinA)</title>
            <description>Dysport® administered in either first intervention period or second intervention period</description>
          </group>
          <group group_id="O2">
            <title>Botox® (onabotulinumtoxinA)</title>
            <description>Botox® administered in either first intervention period or second intervention period</description>
          </group>
        </group_list>
        <measure>
          <title>Reduction of Tsui Score at Each Visit From Baseline</title>
          <description>Tsui scale (range: 0-25, higher values represent worse cervical dystonia.) Negative numbers to represent decreases of Tsui scale.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Reduction in Tsui Score at 8 Weeks from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.33" spread="3.69"/>
                    <measurement group_id="O2" value="-4.23" spread="4.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reduction in Tsui Score at 12 Weeks from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.20" spread="4.48"/>
                    <measurement group_id="O2" value="-3.31" spread="4.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reduction in Tsui Score at 16 Weeks from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.69" spread="3.99"/>
                    <measurement group_id="O2" value="-1.85" spread="4.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CGI-I (Clinical Global Impression of Illness)</title>
        <description>The proportion of patients with ‘normal/ not at all ill’ or ‘borderline mildly ill’ on the CGI (Clinical global impression of illness, CGI-I)
1 = normal / not at all ill’; 2 = ‘borderline mildly ill’; 3 = ‘mildly ill’; 4 = ‘moderlately ill’; 5 = ‘markedly ill’; 6 = ‘severely ill’; 7 = ‘the most extremely ill’.</description>
        <time_frame>4, 8, 12 and 16 weeks after injection</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dysport® (abobotulinumtoxinA)</title>
            <description>Dysport® administered in either first intervention period or second intervention period</description>
          </group>
          <group group_id="O2">
            <title>Botox® (onabotulinumtoxinA)</title>
            <description>Botox® administered in either first intervention period or second intervention period</description>
          </group>
        </group_list>
        <measure>
          <title>CGI-I (Clinical Global Impression of Illness)</title>
          <description>The proportion of patients with ‘normal/ not at all ill’ or ‘borderline mildly ill’ on the CGI (Clinical global impression of illness, CGI-I)
1 = normal / not at all ill’; 2 = ‘borderline mildly ill’; 3 = ‘mildly ill’; 4 = ‘moderlately ill’; 5 = ‘markedly ill’; 6 = ‘severely ill’; 7 = ‘the most extremely ill’.</description>
          <units>percentage of participants scoring 1or2</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>4 weeks after injection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.0"/>
                    <measurement group_id="O2" value="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 weeks after injection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.0"/>
                    <measurement group_id="O2" value="14.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 weeks after injection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.7"/>
                    <measurement group_id="O2" value="14.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>16 weeks after injection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.5"/>
                    <measurement group_id="O2" value="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PGI-I (Patient's Global Impression of Improvement)</title>
        <description>The proportion of patients with 'very much improved' or 'much improved' on the PGI (Patient's global impression of impairment, PGI-I)
1 = very much improved, 2= much improved, 3 = slightly improved, 4 = no change, 5 = slightly aggravated, 6 = much aggravated, and 7 = very much aggravated</description>
        <time_frame>4, 8, 12 and 16 weeks after injection</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dysport® (abobotulinumtoxinA)</title>
            <description>Dysport® administered in either first intervention period or second intervention period</description>
          </group>
          <group group_id="O2">
            <title>Botox® (onabotulinumtoxinA)</title>
            <description>Botox® administered in either first intervention period or second intervention period</description>
          </group>
        </group_list>
        <measure>
          <title>PGI-I (Patient's Global Impression of Improvement)</title>
          <description>The proportion of patients with 'very much improved' or 'much improved' on the PGI (Patient's global impression of impairment, PGI-I)
1 = very much improved, 2= much improved, 3 = slightly improved, 4 = no change, 5 = slightly aggravated, 6 = much aggravated, and 7 = very much aggravated</description>
          <units>percentage of patients scoring 1 or 2</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>4 weeks after injection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.1"/>
                    <measurement group_id="O2" value="36.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 weeks after injection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.0"/>
                    <measurement group_id="O2" value="36.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 weeks after injection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.2"/>
                    <measurement group_id="O2" value="27.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>16 weeks after injection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.4"/>
                    <measurement group_id="O2" value="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Reduction of Total TWSTRS at Each Visit From Baseline</title>
        <description>TWSTRS scale (Toronto western spasmodic torticollis rating scale, range: 0-80, higher values represent worse cervical dystonia.) Negative numbers to represent decreases of TWSTRS scale.</description>
        <time_frame>8, 12 and 16 weeks after injection</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dysport® (abobotulinumtoxinA)</title>
            <description>Dysport® administered in either first intervention period or second intervention period</description>
          </group>
          <group group_id="O2">
            <title>Botox® (onabotulinumtoxinA)</title>
            <description>Botox® administered in either first intervention period or second intervention period</description>
          </group>
        </group_list>
        <measure>
          <title>Reduction of Total TWSTRS at Each Visit From Baseline</title>
          <description>TWSTRS scale (Toronto western spasmodic torticollis rating scale, range: 0-80, higher values represent worse cervical dystonia.) Negative numbers to represent decreases of TWSTRS scale.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Reduction of TWSTRS from Baseline at 8 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.16" spread="10.85"/>
                    <measurement group_id="O2" value="-9.98" spread="9.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reduction of TWSTRS from Baseline at 12 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.95" spread="11.64"/>
                    <measurement group_id="O2" value="-8.66" spread="10.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reduction of TWSTRS from Baseline at 16 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.15" spread="8.73"/>
                    <measurement group_id="O2" value="-5.34" spread="9.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Reduction of Pain Associated With Cervical Dystonia at Each Visit From Baseline</title>
        <description>Pain subscale of TWSTRS scale.(Range: 0-20) Negative numbers to represent decreases of TWSTRS pain subscale.</description>
        <time_frame>4, 8, 12 and 16 weeks after injection</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dysport® (abobotulinumtoxinA)</title>
            <description>Dysport® administered in either first intervention period or second intervention period</description>
          </group>
          <group group_id="O2">
            <title>Botox® (onabotulinumtoxinA)</title>
            <description>Botox® administered in either first intervention period or second intervention period</description>
          </group>
        </group_list>
        <measure>
          <title>Reduction of Pain Associated With Cervical Dystonia at Each Visit From Baseline</title>
          <description>Pain subscale of TWSTRS scale.(Range: 0-20) Negative numbers to represent decreases of TWSTRS pain subscale.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>4 weeks after injections</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.45" spread="4.05"/>
                    <measurement group_id="O2" value="-1.19" spread="4.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 weeks after injections</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.96" spread="3.97"/>
                    <measurement group_id="O2" value="-2.28" spread="3.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 weeks after injections</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.40" spread="4.08"/>
                    <measurement group_id="O2" value="-2.07" spread="3.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>16 weeks after injections</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.97" spread="3.85"/>
                    <measurement group_id="O2" value="-1.76" spread="3.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 Months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Dysport® (abobotulinumtoxinA)</title>
          <description>Dysport® administered in either first intervention period or second intervention period</description>
        </group>
        <group group_id="E2">
          <title>Botox® (onabotulinumtoxinA)</title>
          <description>Botox® administered in either first intervention period or second intervention period</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle weakness</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="94"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="94"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Pain on neck and shoulder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>BS Jeon</name_or_title>
      <organization>Seoul National University Hospital</organization>
      <phone>+82220722876</phone>
      <email>brain@snu.ac.kr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

